In light of recent developments in the realm of mental health parity compliance, both plan sponsors and fiduciaries can now benefit from some much-needed regulatory clarity. This comes following the release of a White House Fact Sheet, accompanied by a comprehensive regulatory package, issued by the US Departments of the Treasury, Labor, and Health and Human Services (the Departments).
The clarity primarily addresses the requirements incorporated into group health plans by the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA). The goals of which are to prevent insurance plans from employing less favorable benefits for mental health conditions as compared to the medical and surgical benefits offered.
The White House Fact Sheet, in relation to the same issue, showcases the Biden-Harris administration’s commitment to enforcing the MHPAEA. As noted in the Fact Sheet, it’s clear that the administration is taking significant steps to improve competition, in an attempt to drive down drug costs for Americans. This initiative is targeted at large pharmaceutical companies, but also extends to health insurance companies and hospital systems.
However, alongside these clarifications, there arise significant questions for stakeholders. Existing uncertainties revolve around the best possible ways for promoting price competition, improving the supply chain, and inhibiting anti-competitive behaviors within the industry. Becoming familiar with these complex issues is crucial for businesses and professionals within the sector.
More extensive insight about these developments can be found in an article by Morgan Lewis, published on JDSupra. This will equip interested parties with a more detailed understanding of these changes, potential challenges, and how best to navigate the dynamic regulatory landscape.